GeneDx Holdings (WGS) Non-Current Assets (2020 - 2026)
GeneDx Holdings' (WGS) quarterly Non-Current Assets came in at $235.1 million in Q2 2026, down 9.23% year-over-year from $259.0 million in Q2 2025, and little changed quarter-over-quarter from $235.7 million in Q1 2026.
Analysis
GeneDx Holdings (WGS) Non-Current Assets (2020 - 2026) Analysis & Trends
GeneDx Holdings (WGS) has reported Non-Current Assets for 7 consecutive years, with $235.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 9.23% year-over-year to $235.1 million in Q2 2026; TTM through Jun 2026 was $982.5 million, a 6.35% increase from a year earlier, with the FY2025 full-year figure at $255.4 million, up 15.36% from the prior year.
- Non-Current Assets was $235.1 million for Q2 2026 at GeneDx Holdings, roughly flat from $235.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $530.6 million in Q2 2022 and troughed at $107.2 million in Q1 2022.
- A 5-year average of $267.8 million and a median of $240.9 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets surged 705.55% in 2022 and tumbled 53.01% in 2023, its largest moves.
- Over 5 years, Non-Current Assets stood at $278.3 million in 2022, then retreated by 15.06% to $236.4 million in 2023, then fell by 6.35% to $221.4 million in 2024, then increased by 15.36% to $255.4 million in 2025, then fell by 7.95% to $235.1 million in 2026.
- The last three Non-Current Assets figures came in at $235.1 million (Q2 2026), $235.7 million (Q1 2026), and $255.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Natera | 53.05 Bn | 51.95 Bn | 486.15 Mn | 998.55 Mn |
| 2 | Quest Diagnostics | 27.19 Bn | 26.87 Bn | 1.03 Bn | 14.10 Bn |
| 3 | Labcorp Holdings | 25.93 Bn | 25.81 Bn | 1.11 Bn | 14.72 Bn |
| 4 | Guardant Health | 23.97 Bn | 22.91 Bn | 219.03 Mn | 547.66 Mn |
| 5 | Tempus AI | 13.64 Bn | 12.82 Bn | 274.25 Mn | 14.60 Mn |
| 6 | Caris Life Sciences | 8.47 Bn | 7.68 Bn | 182.38 Mn | 171.79 Mn |
| 7 | Sotera Health | 5.35 Bn | 4.99 Bn | 177.96 Mn | 2.66 Bn |
| 8 | BillionToOne | 4.96 Bn | 4.41 Bn | 77.11 Mn | 78.32 Mn |
| 9 | Adaptive Biotechnologies | 4.55 Bn | 4.21 Bn | 51.39 Mn | 220.12 Mn |
| 10 | GeneDx Holdings | 3.01 Bn | 2.88 Bn | 78.24 Mn | 235.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 235.13 Mn |
| Mar 31, 2026 | 235.67 Mn |
| Dec 31, 2025 | 255.42 Mn |
| Sep 30, 2025 | 256.32 Mn |
| Jun 30, 2025 | 259.03 Mn |
| Mar 31, 2025 | 220.61 Mn |
| Dec 31, 2024 | 221.41 Mn |
| Sep 30, 2024 | 222.83 Mn |
| Jun 30, 2024 | 226.93 Mn |
| Mar 31, 2024 | 231.10 Mn |
| Dec 31, 2023 | 236.42 Mn |
| Sep 30, 2023 | 245.47 Mn |
| Jun 30, 2023 | 263.11 Mn |
| Mar 31, 2023 | 272.95 Mn |
| Dec 31, 2022 | 278.32 Mn |
| Sep 30, 2022 | 522.36 Mn |
| Jun 30, 2022 | 530.58 Mn |
| Mar 31, 2022 | 107.25 Mn |
| Dec 31, 2021 | 70.55 Mn |
| Sep 30, 2021 | 64.85 Mn |